Showing results 1 to 2 of 2
| Title | Author(s) | Issue Date | |
|---|---|---|---|
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks Journal:Alimentary Pharmacology and Therapeutics | 31-Oct-2023 | ||
Review: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data Journal:Alimentary Pharmacology & Therapeutics | 2022 |